B. Riley Securities Maintains Buy on Agenus, Raises Price Target to $14
Agenus Inc AGEN
$7.50
▼ -5.18%
($-0.41)
📅 Earnings This Week
Open
$7.79
Prev Close
$7.91
Day Range
$7.32 – $7.98
52W Range
$2.71 – $8.70
Market Cap
$335.64M
P/E (TTM)
5.20
Beta
1.42
EPS (TTM)
$1.67
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2000-02-04 |
| Shares Out. | 41,640,000 |
| Website | agenusbio.com/ ↗ |
| Phone | 13026587581 |
| Employees | 81 |
| Revenue | $33.7M |
| Gross Profit | $33.7M |
| Net Income | $39.2M |
| Free Cash Flow | -$87.5M |
| Total Assets | $186.5M |
| Total Liabilities | $414.4M |
| Equity | -$228.0M |
About Agenus Inc
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Agenus Inc is a publicly traded company under the ticker symbol AGEN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-07-01)